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Abstract: The use of methadone for the management of pain has received great interest in recent
years. Currently, oral and intravenous formulations are available for clinical use. Dermal delivery
represents an attractive alternative route of administration for this drug as it is associated with
comparatively fewer side effects. The first stage of the work was the preparation of methadone free
base as this form of the drug is expected to permeate the skin to a greater extent than the hydrochloride
salt. Subsequently the molecule was characterized with Nuclear Magnetic Resonance (NMR) and
thermal analysis, the distribution coefficient was determined and solubility studies were conducted
in a range of solvents. In vitro permeation and mass balance studies were conducted under finite
dose conditions (5 µL/cm2) in porcine skin. The results confirmed the more favorable penetration
of methadone free base compared with the salt. The highest cumulative amount of methadone
(41 ± 5 µg/cm2) permeated from d-limonene (LIM). Ethyl oleate (EO), Transcutol® P (TC) and octyl
salicylate (OSAL) also appear to be promising candidate components of dermal formulations for
methadone base. Future work will focus on further formulation optimization with the objective of
progressing to evaluation of prototype dosage forms in clinical trials.
Keywords: dermal delivery; porcine skin; in vitro permeation; methadone; pain
1. Introduction
Neuropathic pain can be caused by injuries, surgery, chemotherapy and a number of disease
conditions such as diabetes mellitus, cancer and human immunodeficiency virus infection [1]. It
can also arise as a direct consequence of a lesion or disease affecting the peripheral nervous system
or the central nervous system [2]. Patients’ overall health-related quality of life is greatly impacted
by neuropathic pain [3] and it is estimated to affect 7–10% of the general population in Europe [4].
The available current knowledge in terms of causes, diagnosis and treatment for peripheral neuropathic
pain is more advanced than that for pain associated with the central nervous system [5]. However, to
date, there are still very few effective treatments available for management of neuropathic pain.
Methadone has traditionally been used in the management of opioid dependence. However, there
is increasing interest in the repurposing of methadone as a cost-efficient treatment for neuropathic
pain [6,7]. Morley, et al. [8] reported the efficacy of oral methadone for the management of neuropathic
pain in a double-blind randomized controlled crossover trial. 19 patients were enrolled in the trial and
a statistically significant (p < 0.05) improvement in pain relief was reported. Methadone is not only a
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potent µ-opioid receptor agonist but also a non-competitive N-Methyl-d-aspartate (NMDA) receptor
antagonist [9]. The combination of NMDA receptor antagonism and opioid receptor agonism induced
by methadone is thought to result in enhanced analgesic efficacy. Animal studies have demonstrated
that the antinociception effect of methadone is mediated by both opioid agonism and NMDA receptor
antagonism in neuropathic pain [10]. The peripheral effect of morphine, a µ-opioid receptor agonist,
was enhanced by combined administration of (+)-HA966, an NMDA receptor antagonist, in a rat
model of neuropathic pain [11]. In addition, Stoetzer, et al. [12] also suggested that methadone is an
unselective blocker of a number of voltage-gated sodium (Nav) channels including Nav1.2, Nav1.3,
Nav1.7, and Nav1.8 with comparable potency to bupivacaine. These studies suggest that methadone is
a promising candidate to be developed for the management of peripheral neuropathic pain.
Dermal delivery of drugs offers a number of advantages compared with other routes of
administration. Constant drug levels in the plasma can be achieved with a decrease in dosing
frequency. Moreover, the avoidance of first pass metabolism results in less intra- and inter-patient
variability. Dermal delivery should also provide higher concentrations of methadone in skin tissues,
thus targeting pain at its source. The peripheral actions of methadone also suggest a lower concentration
of methadone can be delivered via the skin for pain relief compared with oral administration. To our
knowledge, there are only three published papers that have examined the in vitro skin absorption of
methadone. Fullerton, et al. [13] examined the permeation of methadone in human cadaver skin from
simple ethanol solutions. Ghosh and Bagherian [14] also investigated the delivery of methadone free
base from a transdermal patch in human skin. Recently, Muñoz, et al. [15] reported in vitro permeation
studies using porcine skin to evaluate the efficiency of methadone hydrochloride patches. No studies
have examined the in vivo delivery of this compound through the skin.
The aims of the present work were (i) to prepare and characterize methadone free base and (ii) to
identify effective solvents for the dermal delivery of methadone. A concentration of 5% w/v methadone
base solutions was selected based on available formulations for oral use. A range of solvents, spanning
different physicochemical parameters such as polarity and solubilization properties, were selected as
candidate vehicles. These solvents are generally recognized as safe (GRAS) and are already used in
other topical and transdermal dosage forms.
2. Materials and Methods
2.1. Materials
Methadone hydrochloride, tripropylene glycol (TriPG), dipropylene glycol (DiPG), 1-octanol,
1,3-butanediol (1,3-BD), Brij™ O20, isopropyl myristate (IPM), octyl salicylate (OSAL), oleic acid
(OA) and ethyl oleate (EO) were purchased from Sigma-Aldrich, Dorset, UK. Propylene glycol (PG),
ethyl acetate, d-limonene (LIM), high performance liquid chromatography (HPLC) grade water,
acetonitrile, orthophosphoric acid, 85+%, sodium dihydrogen phosphate, sodium hydrogen phosphate
and sodium hydroxide were supplied by Fisher Scientific, Loughborough, UK. Chloroform-d (CDCl3)
was purchased from Cambridge Isotope Laboratories Tewksbury, MA, USA. Labrafac™ lipophile WL
1349 (medium-chain triglycerides of caprylic and capric acids, WL 1349), Transcutol® (TC), propylene
glycol monocaprylate (PGMC) Type II and propylene glycol monolaurate (PGML) Type II were gifts
from Gattefossé, St. Priest, France. Phosphate buffered saline (PBS) (pH 7.3 ± 0.2 at 25 ◦C) was
prepared using Dulbecco A tablets supplied by Oxoid, Cheshire, UK. Full thickness porcine ear skin
was obtained from a local abattoir.
2.2. Preparation of Methadone Base
Methadone hydrochloride (1.730 g, 0.005 mol) was placed in a dry 250 mL round-bottom flask
with a Teflon coated magnetic stirrer. 20 mL of HPLC grade water was added and the mixture was
stirred for 10 min. The pH was then adjusted to 11.0 with 1 M sodium hydroxide solution. The newly
formed precipitate was stirred for 30 min. 100 mL of ethyl acetate was added to the suspension with
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stirring for 60 min at 25 ◦C. The organic layer was then collected, and the aqueous layer washed
with 45 mL (3 × 15 mL) of ethyl acetate. All organic layers were collected together and dried with
magnesium sulfate. Ethyl acetate was removed using a rotary evaporator (Heidolph, Schwabach,
Germany) using a high vacuum line for 5 h. Structural characterization was conducted using proton
nuclear magnetic resonance (1H-NMR) spectroscopy. The spectrum was obtained in chloroform-d
using a Bruker Avance 500 MHz NMR spectrometer (Bruker Corporation, Billerica, MA, USA) and
processed using MestReNova 11.0.4 (Mestrelab Research, Santiago de Compostela, Spain). The Fourier
transform infrared (FTIR) spectra were obtained with a Bruker Alpha Spectrometer with a Platinum
ATR accessory (Bruker Optics, Coventry, UK) in transmittance mode. Spectral analysis and instrument
control were performed with OPUS software v.7.0 (Bruker Optics). The spectrum of each sample was
measured by taking the average of 64 scans at a resolution of 2 cm−1 at room temperature. The reference
background spectrum was recorded before collecting IR spectra.
2.3. Thermal Analysis
The melting points of methadone hydrochloride and methadone free base were measured
using thermogravimetric analysis (TGA) and differential scanning calorimetry (DSC). Discovery
TGA (TA instruments, Waters, LLC, USA) was used for the degradation temperature identification.
Approximately 3 mg of sample was placed in a tared aluminium pan. A heating ramp of 10 ◦C/min
to 550 ◦C was used during the analysis. A nitrogen flow of 25 mL/min was supplied to create an
inert atmosphere around the sample. A DSC Q2000 (TA instruments) system was used to measure
the melting point. The sample was weighed in a hermetic aluminium pan which was subsequently
sealed with a hermetic aluminium lid using a Tzero press. An empty hermetic aluminium pan sealed
with a hermetic aluminium lid was used as a reference. Sample and reference pans were heated with a
heating ramp of 10 ◦C/min with nitrogen as the purge gas (50 mL/min).
2.4. HPLC Analysis
The HPLC system used in this study consisted of an Agilent G1322A degasser, G1311A quaternary
pump, G1313A auto sampler, G1316A thermostat column compartment and G1315B diode array
detector (Agilent Technologies, Palo Alto, CA, USA.). The software used to acquire and analyze the
data was ChemStation® for LC 3D, Rev. A. 09.03 (Agilent Technologies). Analysis was performed
with a Luna® Omega 5 µm PS C18 150 × 4.60 mm column (Phenomenex, Macclesfield, UK), equipped
with a universal HPLC guard column packed with a SecurityGuard™ C18 cartridge. The mobile phase
consisted of 20 mM sodium phosphate buffer at pH 3 ± 0.2 and acetonitrile (60:40, v/v) and the flow rate
was 1 mL/min. The column temperature and injection volume were set to 30 ◦C and 10 µL, respectively.
Ultraviolet (UV) detection at 213 nm was employed. The HPLC method was validated in terms of
specificity, linearity, accuracy, precision, limit of detection (LOD) and limit of quantification (LOQ)
according to the International Conference of Harmonization guidelines [16]. Calibration curves in the
concentration range of 0.5–100 µg/mL were constructed (r2 ≥ 0.99) and the LOD and LOQ values were
0.23 and 0.69 µg/mL, respectively.
2.5. Log D
The method used for Log D measurement was the shake flask method, adapted from the
Organization for Economic Co-operation and Development (OECD) guidelines [17]. 0.2 M sodium
phosphate buffer solutions were prepared at pH 6.0, 6.5, 7.0, 7.4 and 11.0 and mutually saturated with
1-octanol by slow-stirring (at 130 rpm) for 48 h at 25 ◦C. The solutions were equilibrated in a separation
funnel for 24 h before separation. Methadone solutions in octanol were prepared at 0.1 and 0.5 mmol/L.
These solutions were then mixed with the aqueous phase (sodium phosphate buffers) at three different
ratios (1:1, 2:1 and 1:2). To reach equilibrium, the mixtures were rotated approximately one hundred
times through 180◦ at room temperature. Before sampling, the mixtures were centrifuged at 25 ◦C and
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at 13,000 rpm for 30 min. Samples were taken from each phase with suitable dilution using methanol
and analyzed using the HPLC method described in Section 2.4.
2.6. Solubility and Stability
Stability studies of methadone free base in the Franz cell receptor medium (6% w/v Brij™ O20 in
pH 7.4 PBS) and a range of neat solvents were conducted for 96 h. A known quantity of methadone free
base was dissolved in the receptor medium or neat solvent. These solutions were placed in Eppendorf®
tubes and sealed with Parafilm® before being placed in a shaker (VWR, Leicestershire, UK) at 32 ± 1 ◦C.
Samples were taken at 0, 24, 48, 72 and 96 h. The samples were diluted when necessary and analyzed
using the HPLC method described in Section 2.4.
The solubility parameter values (δ) of the solvents were calculated by the van Krevelen-Hoftyzer
approach [18] using Molecular Modelling Pro® Version 6.3.3 software (ChemSW, Fairfield, CA, USA).
In total, 13 different single solvents were selected for solubility studies in order to ensure that solvents
with a wide range of solubility parameter values were investigated. Solubility studies were also
conducted with PBS and PBS with 6% Brij™ O20 (w/v) solution to confirm that sink conditions would
be maintained during the in vitro permeation studies.
For solubility determinations, an excess amount of methadone hydrochloride or free base was
added to 0.5 mL of each solvent in Eppendorf® tubes (n = 3). The tubes were sealed with Parafilm®
and placed on a rotator at 32 ± 2 ◦C for at least 48 h. These samples were then centrifuged at 12,000 rpm
for 15 min at 32 ± 1 ◦C. The supernatant was suitably diluted to lie within the range of the calibration
curve of the validated HPLC method, described in Section 2.4.
2.7. In Vitro Permeation and Mass Balance Studies
In vitro permeation studies were carried out as reported previously by Santos, et al. [19] using
vertical glass Franz diffusion cells. Full thickness porcine ear skin was separated from the underlying
tissue at room temperature and then stored at −20 ◦C before use. Skin integrity was assessed by
measuring impedance at a frequency of 50 Hz before applying formulations [20]. The diffusion area was
~1 cm2 and was accurately measured before application of finite doses (5 µL/cm2) of 5% w/v methadone
base solutions. The complete dissolution of methadone in all solvents was confirmed in the preparation
of formulations. 6% w/v Brij™ O20 was added to the receptor phase, PBS pH 7.3 ± 0.2 to ensure the
concentration of methadone never exceeded 10% of its solubility without affecting the integrity of the
skin [21,22]. Sink conditions in this medium were therefore confirmed during experiments. Permeation
studies were performed for 24 h at 32 ± 1 ◦C. 200 µL samples were withdrawn from the receptor
compartment and replaced with 200 µL of fresh receptor medium at 0, 2, 4, 6, 8, 10, 12, 24 h.
Validated mass balance studies were performed after each permeation study. The skin surfaces
were washed three times with 1 mL of methanol. The skin was then placed in Eppendorf® tubes
with 1 mL of methanol. The samples for skin extraction were placed in a shaker overnight to extract
methadone. All Eppendorf ® tubes were centrifuged at 13,000 rpm at 32 ◦C for 15 min before sampling.
The supernatants were sampled and diluted where necessary and analyzed by HPLC.
2.8. Statistical Analysis
Microsoft Excel® 2016 was used for data processing and the calculation of mean and standard
deviation (SD). IBM® SPSS Statistics® 24.0 (IBM SPSS Statistics, Feltham, UK) was used for statistical
analysis. The Shapiro-Wilk test was used to assess the normality of the data. If the p value calculated
from the test was higher than 0.05, the data were assumed to be normally distributed. For normally
distributed data (parametric data), the independent-samples t test and one-way analysis of variance
(ANOVA) with Tukey’s HSD post hoc test were used to analyze two groups and ≥3 groups respectively.
For non-normally distributed data (non-parametric data), the Mann-Whitney U test was used to
test statistical significance between two groups and the Kruskal-Wallis one-way ANOVA test was
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performed to investigate statistical differences among different groups (≥3 groups). A probability of p
< 0.05 was considered as a statistically significant difference.
3. Results and Discussion
3.1. Characterization of Methadone Free Base with NMR and IR Spectroscopy
The 1H-NMR spectrum of methadone hydrochloride is shown in Figure 1. A singlet at 12.00 ppm
suggests the protonation of the tertiary amine while the 1H-NMR spectrum of methadone free base
shows that there is no singlet around 12.00 ppm for the hydrochloride proton (Figure 2). In addition,
all spectral peaks were assigned for both methadone hydrochloride and free base. A water singlet at
1.61 ppm in both spectra may reflect small amounts of water present in the samples [23]. These results
confirm the successful conversion of methadone hydrochloride to the free base. Methadone free base
was obtained as a white powder, with a yield of 92%. The IR spectra of methadone free base and
methadone hydrochloride also support the conclusion that methadone hydrochloride was successfully
converted to methadone free base (Figure S1). Characteristic peaks for methadone were obtained for
both methadone hydrochloride and free base; a broad band at 2399 cm−1 was assigned to the NH+
stretching of methadone hydrochloride.
Figure 1. 1H-NMR spectrum of methadone hydrochloride in chloroform-d. 1H-NMR (500 MHz,
Chloroform-d) δ 12.00 (s, 1H), 7.48–7.35 (m, 8H), 7.25–7.19 (m, 2H), 3.09 (q, 1H), 3.02 (d, 1H), 2.79 (d,
3H), 2.68 (d, 3H), 2.45 (dq, 1H), 2.26–2.14 (m, 2H), 0.86 (t, 3H), 0.73 (d, 3H). A singlet at 12.00 ppm
suggests the protonation of the tertiary amine.
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Figure 2. 1H-NMR spectrum of methadone free base in chloroform-d. 1H-NMR (500 MHz,
Chloroform-d) δ 7.42 (dd, 1.6 Hz, 2H), 7.36–7.30 (m, 6H), 7.28–7.24 (m, 2H), 2.88 (dd, J = 13.9,
5.5 Hz, 1H), 2.46–2.36 (m, 2H), 2.31 (dq, 7.2 Hz, 1H), 2.14 (s, 6H), 2.02 (dd, J = 13.9, 5.6 Hz, 1H), 0.86 (t,
3H), 0.49 (d, 3H). The 1H-NMR spectrum of methadone free base shows that there is no singlet around
12.00 ppm for the hydrochloride proton.
3.2. Thermal Analysis
The thermogravimetric analysis of methadone hydrochloride and methadone free base is shown
in Figure S3. The decomposition of methadone hydrochloride is evident from 167 to 261 ◦C (onset:
230.12 ◦C) while that of methadone free base occurs from 134 to 230 ◦C (onset: 194.35 ◦C).
The DSC thermograms of methadone hydrochloride and the free base are shown in Figure 3.
The melting points of methadone free base and methadone hydrochloride were obtained as the
onset temperatures. The melting point of methadone hydrochloride (235.54 ◦C) is very close to the
degradation temperature of the compound. Only one endothermic event which occurs between 73.5 ◦C
and 79.8 ◦C was observed for methadone free base. The obtained melting point of methadone free base
is 74.00 ◦C which is consistent with the literature (76 ◦C) [24].
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Figure 3. DSC thermograms of methadone hydrochloride and methadone free base.
3.3. Log D Measurement
The predicted values of the Log P for methadone base from ChemAxon and ACD/Labs were
5.0 and 4.2, respectively. These values are higher than the experimental Log P value of 3.93 reported
previously [25]. The measurement of the partition coefficient of an ionizable species should be made in
the non-ionized form according to the OECD guidelines [17]. An appropriate buffer with a pH of at
least one unit above the dissociation constant (pKa) of methadone (pKa = 8.94) [26] should be used to
ensure the compound is present as the free base. Hence, 20 mM pH 11 PBS was used in this study to
measure the partition coefficient of methadone base. The value obtained in this measurement was
4.85 ± 0.03. The Log D values obtained at different pH values are listed in Table 1. The log D value at
pH 7.4 is lower than the experimental value previously reported (Log D7.4 = 2.1) [27], however no
details of the buffer or ionic strength used were given for this earlier measurement.
Table 1. Distribution coefficient of methadone for different pH values at 25 ± 1 ◦C.
pH Log D
6.0 0.31 ± 0.01
6.5 0.80 ± 0.01
7.0 1.35 ± 0.01
7.4 1.82 ± 0.01
11.0 (free base) 4.85 ± 0.03
3.4. Stability and Solubility
After 96 h stability studies at 32 ± 1 ◦C, the recovery values of methadone base in all solvents was
>97%. The chemical stability of methadone free base over 96 h in the receptor medium for permeation
studies and common solvents, including LIM, EO, IPM, WL 1349, OA, PGML, PGMC, TC, OSAL,
TriPG, DiPG, PG, 1,3-BD and ethyl acetate, was confirmed (Figure S4).
The solubility values for methadone hydrochloride in water and ethanol have been reported
previously as 120 and 80 mg/mL, respectively [28]. The solubility of methadone hydrochloride and
free base at 32 ± 1 ◦C was measured in a range of solvents (Table 2). As expected, methadone
hydrochloride is poorly soluble in solvents such as LIM, EO, IPM and OSAL and relatively high
solubility was observed for hydrophilic solvents. The highest solubility of methadone hydrochloride
was observed in PG. The solubility values for methadone free base and its hydrochloride salt in PBS are
0.49 ± 0.01 and 86.66 ± 0.95 mg/mL, respectively. The addition of 6% w/v Brij™O20 in PBS increased the
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solubility of methadone free base and methadone hydrochloride to 2.61± 0.02 and 107.45 ± 1.35 mg/mL,
respectively. Methadone free base has a calculated van Krevelen and Hoftyzer solubility parameter
of 10.07 (cal/cm3)1/2 and its solubility in solvents with solubility parameters, ranging from 8 to 11
(cal/cm3)1/2 was >100 mg/mL (Figure 4). These results are consistent with the theory proposed by
Hancock, et al. [29] i.e., when the solubility parameters of solute and solvent are similar, high solubility
is expected compared with solvents that do not have similar solubility parameters. On the other
hand, solubility parameters only provide an indication of solubility characteristics and cannot account
for all circumstances. Molecules may take up different conformations in the various solvents and
anomalies are possible. It is interesting to note that methadone base has relatively low solubility in
hydrophilic solvents with solubility parameter value above 11 (cal/cm3)1/2 and it showed a lower
solubility in TriPG compared with OSAL. The anomalous solubility behavior of caffeine was also
reported previously [30–32].
Table 2. Summary of the solubility of methadone hydrochloride and free base in neat solvents at
32 ± 1 ◦C. The solubility parameter of methadone free base is 10.07 (cal/cm3)1/2.
Solvent Solubility of Methadone base(mg/mL)
Solubility of Methadone
Hydrochloride (mg/mL)
LIM 342.38 ± 2.99 0.08 ± 0.002
EO 205.46 ± 1.69 0.08 ± 0.01
IPM 179.80 ± 0.89 0.03 ± 0.001
WL 1349 217.66 ± 3.73 0.05 ± 0.001
OA 438.76 ± 2.56 2.53 ± 0.03
PGML 209.43 ± 0.54 19.68 ± 0.79
PGMC 250.74 ± 2.17 28.65 ± 0.46
TC 247.68 ± 0.95 21.96 ± 0.46
OSAL 277.20 ± 6.96 0.05 ± 0.001
TriPG 105.90 ± 0.25 18.03 ± 0.93
DiPG 85.94 ± 0.41 43.97 ± 1.28
PG 24.78± 0.49 201.33 ± 1.30
1,3-BD 26.24 ± 0.05 88.40 ± 0.79
PBS 0.49 ± 0.01 86.66 ± 0.95
PBS + 6% w/v Brij™ O20 2.61 ± 0.02 107.45 ± 1.35
Figure 4. Solubility of methadone free base and methadone hydrochloride in solvents at 32 ± 1 ◦C and
solubility parameters of solvents.
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3.5. In Vitro Permeation and Mass Balance Studies of Methadone Base in Porcine Ear Skin
Eight solvents were selected for in vitro permeation studies of methadone free base in porcine skin
under finite dose conditions (5 µL/cm2). The permeation profiles are shown in Figure 5. The highest
permeation of methadone was observed for LIM (p < 0.01). The cumulative amount of methadone
that permeated after 24 h was 41.3 ± 4.7 µg/cm2 (20.7 ± 2.3% of the applied dose). The results also
suggest EO, TC and OSAL are promising vehicles for methadone. Although methadone hydrochloride
permeation in PG was investigated also, the maximum cumulative amount that permeated through
porcine skin after 24 h was only 2.5 ± 0.6 µg/cm2.
Figure 5. Cumulative permeation profiles of methadone in porcine skin after application of 5% (w/v)
methadone free base in LIM (), EO (), TC (N), OSAL (×), PGML (#), WL 1349 (), TriPG () and OA
(+) for finite dose (5 µL/cm2) at 32 ± 1 ◦C. Each data point represents the mean ± SD (mean ± SD; 4 ≤ n
≤ 5). ** p < 0.01.
Mass balance studies confirm that high permeation of methadone generally was associated with
high amounts of drug extracted from the skin (Figure 6). Except for LIM, the overall recoveries for other
formulations were within the recovery range (90–110%) recommended in the OECD guidelines [33].
Although the stability of methadone free base in formulations and the receptor fluid was confirmed,
the overall recovery of methadone for LIM was only 86.33 ± 2.15%. However, LIM still delivered
significantly higher (p < 0.05) percentages of methadone into the skin and through the skin compared
with the other solvents. The results confirm that the lowest percentage of methadone recovered from
the skin surface was observed for LIM, followed by EO, OSAL and TC (Figure 6). Except for LIM, the
percentages of applied methadone recovered from the skin surface were significantly higher compared
with the percentages of methadone inside skin and permeated across skin.
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Figure 6. Mass balance results after 24 h finite dose (5 µL/cm2) permeation studies in porcine skin for
5% (w/v) methadone free base in LIM, EO, TC, OSAL, PGML, WL 1349, TriPG and OA at 32 ± 1 ◦C
(mean ± SD; 4 ≤ n ≤ 5). ** p < 0.01.
A proposed mechanism of penetration enhancement for LIM is the disruption of the highly ordered
structure of intercellular lipids which may result in an increase in drug diffusion [34]. The permeation
of LIM through human skin and high affinity of LIM for the epidermis were reported by Cal, et al. [35].
This indicates another potential mechanism that may contribute to high permeation of methadone in
the present study. With the exception of OA, the highest solubility of methadone base was observed
for LIM. The uptake of LIM into skin may create a more favorable environment for methadone and
thus increase the partition of methadone into the stratum corneum (SC). In addition, both skin uptake
and evaporation of LIM can also contribute to an increase in the thermodynamic activity of methadone
and the partition into skin. On the other hand, drug crystallization inside the skin or on the skin
surface may occur as well when LIM permeates through skin. LIM is generally recognized as a safe
ingredient in topical products [36]; the highest concentration used in FDA approved topical products
is 10% w/w [37].
EO is derived from the esterification of OA with ethanol. Both EO and OA have a double bond in
the cis configuration, forming a “kinked” shape [38]. This kink conformation may disrupt SC lipid
packing by introducing a separate phase in the intercellular lipid domain and thus increase the diffusion
of solute through skin [39,40]. The permeation of methadone for OA was significantly lower than that
for EO and other solvents (p < 0.05). This may reflect electrostatic interaction between methadone
free base and the carboxylic acid group of OA. The presence of ionized methadone might also be
expected to reduce the partition of methadone from OA into SC lipids, thus reducing the permeation of
methadone. FTIR was subsequently used to confirm an interaction between methadone free base and
OA (Figure S2). The high solubility of methadone in OA reported above also supports the possibility
of an interaction between OA and methadone free base.
The cumulative amount of methadone that permeated through skin for OSAL was significantly
higher than for PGML and medium-chain triglycerides of caprylic and capric acids (WL 1349) (p < 0.05)
while there is no significant difference between the amounts of methadone extracted from skin for
these solvents (p > 0.05). This indicates that OSAL is more likely to enhance permeation by increasing
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the diffusion of methadone through skin rather than altering the partition of methadone into stratum
corneum. Santos, et al. [41] reported that OSAL is taken up to a high extent by the skin but no effect on
lipid fluidity was observed using DSC and FTIR. The authors proposed that OSAL may enhance drug
diffusion by creating “pools” of solvent within the gel lipid phase.
The cumulative amount of methadone that permeated through porcine skin from TC after 24
h was 21.07 ± 5.12 µg/cm2. Almost double the amount of methadone was recovered following skin
extraction compared with the amount that permeated for this vehicle. TC is miscible with both polar
and non-polar solvents and it has been widely used as a penetration enhancer. Haque, et al. [42]
reported that 53.4% of TC permeated through human skin in Franz cell studies by 19 h. The rapid
skin uptake of TC suggest that TC is likely to enhance permeation by increasing drug solubility in
intracellular lipids. TC may therefore play a key role in driving the partition of methadone into
skin and increasing permeation. Increasing thermodynamic activity of methadone resulting from TC
evaporation and skin uptake may also contribute to the skin permeation of methadone. The highest
concentrations of TC, OSAL and EO used in FDA approved topical products are 49.91% w/w, 8.5% w/w
and 0.14 mg/mL, respectively [37].
Fullerton et al. [13] evaluated the transdermal delivery of methadone free base using human
cadaver skin over 24 h. Solutions of methadone base were prepared in ethanol and propylene
glycol and in ethanol and propylene glycol with either oleic acid or Azone®. The highest amount of
methadone permeated from the ethanol: PG: Azone solution (~400 µg/cm2), however the concentration
of methadone (720 µg/µL) was more than 10-fold greater than that evaluated in the present work.
Ghosh and Bagherian [14] also investigated a transdermal patch containing methadone free base in
human skin. Patches with or without 5% w/w Azone® or 5% w/w n-decylmethyl sulfoxide were tested.
The cumulative amounts of methadone permeation at 24 h in human skin ranged from 1 to 3 mg/cm2.
Again, comparisons with the present work are limited because of the comparatively larger doses of
methadone in the patches compared with the formulations examined here. It is also important to note
that the objectives of these two earlier studies were systemic delivery of methadone for management
of substance abuse rather than local delivery.
4. Conclusions
Methadone free base was prepared from its hydrochloride salt, followed by a series of
characterization studies. A range of solvents was evaluated using in vitro permeation and mass
balance studies in porcine skin and a maximum skin flux of 2.54 ± 0.19 µg/cm2/h was estimated. The
results suggest that TC, LIM, OSAL and EO appear to be promising candidate vehicles for dermal
delivery of methadone base. This is the first study to confirm skin permeation of methadone base
under finite dose conditions. However, for most formulations the majority of the active remained
on the skin surface after 24 h. Future work will focus on development of more complex vehicles
with further optimization and evaluation of skin permeation in human skin. The most promising
formulations will be progressed for investigation in the clinic.
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oleic acid and (B) 10mg methadone free base dissolved in 0.1 mL oleic acid (OA), Figure S3: Thermogravimetric
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in a series of neat after 24, 48, 72 and 96 h at 32 ± 1 ◦C (n = 3; mean ± SD).
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Abbreviations
1,3-BD 1,3-butanediol
1H-NMR Proton Nuclear Magnetic Resonance
ANOVA One-way Analysis of Variance
CDCl3 Chloroform-d
DiPG Dipropylene Glycol
DSC Differential Scanning Calorimetry
EO Ethyl Oleate
FTIR Fourier Transform Infrared
GRAS Generally Recognized as Safe
HPLC High Performance Liquid Chromatography
IPM Isopropyl Myristate
LIM d-limonene
LOD Limit of Detection
Log D Logarithm to the Base 10 of Distribution Coefficient
Log P Logarithm to the Base 10 of Partition Coefficient
LOQ Limit of Quantification
Nav Voltage-gated Sodium (Nav) Channels
NMDA N-Methyl-d-aspartate
OA Oleic Acid
OECD Organisation for Economic Co-operation and Development
OSAL Octyl Salicylate
PBS Phosphate Buffered Saline
PG Propylene Glycol
PGMC Propylene Glycol Monocaprylate
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